Soil-transmitted helminths (STHs) are common nematode parasites of the human intestinal tract. The main STHs are Ascaris, hookworms, and whipworms. These parasites infect > 400,000,000 children worldwide, leading to significant malnutrition, physical stunting, cognitive deficiencies, school absenteeism, lower future earnings, lower educational status, vaccine failure, and immune deficiencies. The parasites also complicate pregnancies, cause lethargy, and result in low worker productivity in adults. Recent estimates have placed the burden of STH disease comparable of that malaria and cancer. In all these ways, the devastating impact of STH infections affect childhood health and development, maternal and adult health, and economic productivity in such a way as to trap endemic communities in a cycle of poverty, underdevelopment, and disease. Currently only one drug, albendazole, has adequate efficacy for single-dose mass drug administration. Albendazole has moderate and highly variable efficacy against hookworms and very poor efficacy against whipworms. Recent data have revealed instances of unusually low or reduced efficacy of albendazole over time against hookworms and Ascaris. New and improved classes of anthelmintics to treat STHs are urgently needed. This project proposes a radical new approach for deworming-use of the vertebrate-safe Bacillus thuringiensis crystal (Cry) protein, Cry5B (and potentially Cry14A), delivered via potent and unique formulations or via an engineered probiotic bacterium, Bacillus subtilis natto. Cry proteins are generally regarded as safe to humans. When given orally, single-dose Cry5B can cure hookworm infections in hamsters and Ascaris infections in pigs; whipworms are sensitive to Cry5B in vitro. Cry5B efficacy can be boosted using biological encapsulations. Probiotic Bacillus subtilis natto, eaten for centuries by the Japanese, can be engineered to express bioactive Cry5B with strong anthelmintic properties.
The aims of this project are (Aim 1) to optimize biological formulation of Cry5B protein and expression of Cry5B in probiotic B. subtilis natto, testing in vitro activity against all the parastes and in vivo activity against hookworms and whipworms in rodents and Ascaris in pigs;
(Aim 2) develop and test against all parasites the next generation Cry protein anthelmintic with promising properties, Cry14A;
and (Aim 3) investigate potential powerful synergistic drug combinations with Cry5B to delay or prevent the evolution of parasite resistance. At the conclusion of this study, we will select a delivery form of Cry5B to be advanced into pre-clinical and future clinical trials based upon 1) highest efficacy against parasites in vivo, 2) lowest delivery cost, and 3) discussions with regulators (FDA).

Public Health Relevance

Soil transmitted helminths (hookworms, whipworms, Ascaris) are major parasites of the human that cause many adverse outcomes including malnutrition, physical stunting, cognitive defects, lower earning and educational status, lethargy, immune deficiencies, adverse pregnancy outcomes, and lower productivity. Resistance and low efficacy to current drugs is growing and new therapies are urgently needed. This project will produce a new, potent, and safe therapeutic for these parasites-a biologically encapsulated protein or engineered bacterial probiotic that cures these parasites in humans.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI056189-13
Application #
9057439
Study Section
Drug Discovery and Mechanisms of Antimicrobial Resistance Study Section (DDR)
Program Officer
O'Neil, Michael T
Project Start
2003-07-01
Project End
2019-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
13
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Massachusetts Medical School Worcester
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
Hu, Yan; Nguyen, Thanh-Thanh; Lee, Alice C Y et al. (2018) Bacillus thuringiensis Cry5B protein as a new pan-hookworm cure. Int J Parasitol Drugs Drug Resist 8:287-294
Papaiakovou, Marina; Pilotte, Nils; Baumer, Ben et al. (2018) A comparative analysis of preservation techniques for the optimal molecular detection of hookworm DNA in a human fecal specimen. PLoS Negl Trop Dis 12:e0006130
Tyagi, Rahul; Maddirala, Amarendar Reddy; Elfawal, Mostafa et al. (2018) Small Molecule Inhibitors of Metabolic Enzymes Repurposed as a New Class of Anthelmintics. ACS Infect Dis 4:1130-1145
Chen, Huan-Da; Kao, Cheng-Yuan; Liu, Bang-Yu et al. (2017) HLH-30/TFEB-mediated autophagy functions in a cell-autonomous manner for epithelium intrinsic cellular defense against bacterial pore-forming toxin in C. elegans. Autophagy 13:371-385
Noon, Jason B; Aroian, Raffi V (2017) Recombinant subunit vaccines for soil-transmitted helminths. Parasitology 144:1845-1870
Dementiev, Alexey; Board, Jason; Sitaram, Anand et al. (2016) The pesticidal Cry6Aa toxin from Bacillus thuringiensis is structurally similar to HlyE-family alpha pore-forming toxins. BMC Biol 14:71
Durmaz, Evelyn; Hu, Yan; Aroian, Raffi V et al. (2016) Intracellular and Extracellular Expression of Bacillus thuringiensis Crystal Protein Cry5B in Lactococcus lactis for Use as an Anthelminthic. Appl Environ Microbiol 82:1286-94
Schwarz, Erich M; Hu, Yan; Antoshechkin, Igor et al. (2015) The genome and transcriptome of the zoonotic hookworm Ancylostoma ceylanicum identify infection-specific gene families. Nat Genet 47:416-22
Wu, Chia-Chen; Hu, Yan; Miller, Melanie et al. (2015) Protection and Delivery of Anthelmintic Protein Cry5B to Nematodes Using Mesoporous Silicon Particles. ACS Nano 9:6158-67
Somvanshi, Vishal S; Ellis, Brian L; Hu, Yan et al. (2014) Nitazoxanide: nematicidal mode of action and drug combination studies. Mol Biochem Parasitol 193:1-8

Showing the most recent 10 out of 25 publications